Affiliation:
1. University of New South Wales
2. St George Hospital
3. Kossard Dermatopathology
Abstract
Exfoliative cheilitis is an inflammatory condition that can significantly impair quality of life. This is the first reported case of an interleukin-23 inhibitor, tildrakizumab, for the treatment of a chronic, refractory case of exfoliative cheilitis.